Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Hematopoietic and Lymphatic System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Hematopoietic and Lymphatic System Neoplasm

Cancer Family

Hematopoietic and Lymphatic System Neoplasm

CI-CAN-00000022Explore in graph →

Non-malignant4,304 active trials98 approved drugs1,010 evidence items

NCIt: C35813

Overview
Statistics
Survival
Genomics60
Variants & evidence1010
Drugs99
Trials18827
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (736)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 551–575 of 736 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
· Blood · 2012 · PMID 22383795 · validated civic_curation pubmed
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
· N Engl J Med · 2015 · PMID 26352686 · validated civic_curation pubmed
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
· Leukemia · 2017 · PMID 27568520 · validated civic_curation pubmed
Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.
· J Exp Clin Cancer Res · 2009 · PMID 19284554 · validated civic_curation pubmed
IDH1 inhibitor shows promising early results.
· Cancer Discov · 2015 · PMID 25583779 · validated civic_curation pubmed
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
· BMC Cancer · 2016 · PMID 27485109 · validated civic_curation pubmed
Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications.
· Blood · 2014 · PMID 24335498 · validated civic_curation

Showing 551–575 of 736 publications

← Previous
1
…
22
23
24
…
30
Next →

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

· Blood · 2007 · PMID 17264298 · validated civic_curation pubmed

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

· Blood · 2005 · PMID 15459012 · validated civic_curation pubmed

A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia.

· Br J Haematol · 2002 · PMID 12060124 · validated civic_curation pubmed

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.

· Blood · 2011 · PMID 21613260 · validated civic_curation pubmed

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

· Proc Natl Acad Sci U S A · 2004 · PMID 15448205 · validated civic_curation pubmed

Crizotinib in anaplastic large-cell lymphoma.

· N Engl J Med · 2011 · PMID 21345110 · validated civic_curation pubmed

In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.

· Blood · 2002 · PMID 11830488 · validated civic_curation pubmed

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.

· Oncotarget · 2016 · PMID 27626698 · validated civic_curation pubmed

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

· Blood · 2003 · PMID 12623848 · validated civic_curation pubmed

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

· N Engl J Med · 2006 · PMID 16775234 · validated civic_curation pubmed

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

· Nature · 2015 · PMID 25686603 · validated civic_curation pubmed

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.

· Leuk Res Rep · 2014 · PMID 25180155 · validated civic_curation pubmed

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.

· J Clin Invest · 2018 · PMID 29920189 · validated civic_curation pubmed

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.

· Blood · 2017 · PMID 28408464 · validated civic_curation pubmed

Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.

· Blood Adv · 2019 · PMID 31725893 · validated civic_curation pubmed

A new genomic framework to categorize pediatric acute myeloid leukemia.

· Nat Genet · 2024 · PMID 38212634 · validated civic_curation pubmed

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.

· Nat Genet · 2015 · PMID 26214592 · validated civic_curation pubmed

Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion.

· Pathol Oncol Res · 2022 · PMID 36172171 · validated civic_curation pubmed